Lanean...
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an at...
Gorde:
| Argitaratua izan da: | J Immunother Cancer |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5987486/ https://ncbi.nlm.nih.gov/pubmed/29866197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0361-7 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|